 Connection
David Camidge to Precision Medicine
This is a "connection" page, showing publications David Camidge has written about Precision Medicine.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.247 |
|
|
|
-
Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol. 2019 06; 16(6):341-355.
Score: 0.129
-
Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012 Mar 13; 106(6):1100-6.
Score: 0.078
-
Venook AP, Arcila ME, Benson AB, Berry DA, Camidge DR, Carlson RW, Choueiri TK, Guild V, Kalemkerian GP, Kurzrock R, Lovly CM, McKee AE, Morgan RJ, Olszanski AJ, Redman MW, Stearns V, McClure J, Birkeland ML. NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw. 2014 Nov; 12(11):1629-49.
Score: 0.023
-
Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular origins of lung cancer: prospects for personalized prevention and therapy. J Thorac Oncol. 2010 Jun; 5(6 Suppl 3):S207-13.
Score: 0.017
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|